

# A Chapter on:

## **Prenatal Cytogenetic Analysis: Methods, Applications, and Clinical Implications**

### **Author information:**

**Ankita Bhatiya\*1,**

\* 1Smt.L.P.Patel Institute of Medical Laboratory Technology,

Bhaikaka University,

Karamsad, Gujarat, India.

Email: [ankitarb@charutarhealth.org](mailto:ankitarb@charutarhealth.org)

ORCID: 0000-0003-3584-8442

Contact number: + 91 8460094834

**Disclaimer:** The author(s) ensure that no contractual relations or proprietary considerations exist that would affect the publication of information in the submitted manuscript. There is no conflict of interest of any sort. Neither has the membership nor one with substantially similar content under my authorship been published in any language, in any journal nor is being considered for publication elsewhere.

**Number of Figure: 00**

**Number of Table: 00**

# Prenatal Cytogenetic Analysis: Methods, Applications, and Clinical Implications

## I. ABSTRACT

Prenatal cytogenetic analysis plays a crucial role in the field of reproductive medicine, aiding in the diagnosis and management of genetic abnormalities in unborn fetuses. This chapter provides an in-depth exploration of the various methods and techniques utilized in prenatal cytogenetic analysis, along with its applications and clinical significance. Understanding the advancements and challenges in this field is essential for healthcare professionals and researchers to offer accurate and timely genetic counseling and informed decision-making for expectant parents.

## II. INTRODUCTION

### (a) Overview of Prenatal Cytogenetic and its Importance:

Prenatal cytogenetic is the branch of genetics and medicine that focuses on the study of chromosomes in developing fetuses to identify any chromosomal abnormalities before birth. Chromosomal abnormalities are genetic conditions caused by the alteration in the number or structure of chromosomes. They can lead to developmental disabilities, birth defects, or even pregnancy loss.<sup>(1)</sup>

#### **Prenatal cytogenetic testing is crucial for various reasons:**

- Early detection of chromosomal abnormalities allows parents to make informed decisions about the continuation of the pregnancy and prepares them for the challenges that may lie ahead.
- It helps healthcare professionals in providing appropriate medical care and support to the parents and the affected child.

Prenatal genetic testing enables genetic counseling, which assists parents in understanding the risks and possible outcomes associated with the genetic condition.<sup>(2)</sup>

### (b) Historical Development and Milestones in Prenatal Genetic Testing:

- 1950s: The discovery of the structure of DNA by Watson and Crick laid the foundation for understanding genetic principles, and prenatal genetic testing started to gain attention.
- 1966: The first successful amniocentesis procedure was performed for prenatal diagnosis of a chromosomal abnormality.
- 1970s: Techniques for culturing and analyzing fetal cells obtained through amniocentesis or chorionic villus sampling (CVS) were developed, leading to improved accuracy in prenatal cytogenetics.
- 1980s: Prenatal screening tests like maternal serum screening and ultrasound scans became more widely used to identify high-risk pregnancies that may require further genetic testing.
- 1990s: The advent of fluorescence in situ hybridization (FISH) allowed for rapid and targeted analysis of specific chromosomal abnormalities.
- Early 2000s: Array comparative genomic hybridization (aCGH) was introduced, enabling the detection of submicroscopic chromosomal imbalances not visible through conventional methods.
- Recent years: The rise of next-generation sequencing (NGS) and non-invasive prenatal testing (NIPT) revolutionized prenatal genetic testing, offering higher resolution and reduced risk for the fetus.<sup>(1)</sup>

### (c) Ethical Considerations and Informed Consent in Prenatal Cytogenetic Analysis:

Ethical considerations play a significant role in prenatal cytogenetic analysis due to the complex nature of genetic testing and the potential impact on the family and the unborn child. Key ethical considerations include:

- **Informed Consent:** Healthcare providers must ensure that expectant parents fully understand the purpose, benefits, risks, and limitations of prenatal cytogenetic testing before obtaining their informed consent. Informed consent ensures that individuals have the autonomy to make decisions based on complete information.
- **Confidentiality and Privacy:** Genetic information is sensitive and requires strict confidentiality to protect the privacy of the family. Appropriate measures must be taken to secure and handle genetic data.
- **Non-Directive Counseling:** Genetic counselors should provide unbiased and non-directive counseling, respecting the values and beliefs of the parents. They should assist parents in making decisions based on their own preferences.

- Reproductive Autonomy:** Prenatal genetic testing raises questions about reproductive choices, including abortion. Respect for reproductive autonomy is essential, allowing parents to make decisions in line with their values and cultural beliefs.
- Pre- and Post-Test Counseling:** Genetic counseling should be provided both before and after the test to help parents understand the implications of test results and the available options.
- Equity and Accessibility:** Ethical considerations extend to ensuring equitable access to prenatal genetic testing, regardless of socioeconomic status, race, or ethnicity.<sup>(1,2,3)</sup>

### III. SAMPLE COLLECTION AND PREPARATION

•**Techniques for obtaining prenatal samples:** Amniocentesis, chorionic villus sampling (CVS), percutaneous umbilical blood sampling (PUBS), and non-invasive prenatal testing (NIPT).

•**Sample handling, fixation, and transport to ensure reliable results.**

Prenatal cytogenetic analysis requires the collection of fetal cells or genetic material from the developing fetus for chromosomal testing. Different techniques are employed for obtaining prenatal samples, each with its advantages, limitations, and specific indications. Proper sample handling, fixation, and transportation are critical to ensure reliable and accurate results in prenatal genetic testing.

**(a)Amniocentesis:** Amniocentesis is one of the most commonly used invasive procedures for obtaining prenatal samples. It is typically performed between 15 to 20 weeks of gestation. During the procedure, a small amount of amniotic fluid surrounding the fetus is withdrawn using a fine needle under ultrasound guidance. The amniotic fluid contains fetal cells, including cells shed from the fetal skin, which can be used for chromosomal analysis.

**Sample Handling and Transport:** After collection, the amniotic fluid sample is transported to the laboratory in a sterile container. The sample should be handled with care to prevent contamination and should be kept at room temperature during transport. In the laboratory, the fluid is processed to isolate fetal cells for further culturing and chromosomal analysis.<sup>(4)</sup>

**(b)Chorionic Villus Sampling (CVS):** CVS is performed between 10 to 13 weeks of gestation and involves the removal of a small tissue sample from the chorionic villi, which are finger-like projections of the placenta. The chorionic villi share the same genetic makeup as the fetus, making them suitable for chromosomal testing.

**Sample Handling and Transport:** The collected chorionic villi sample is usually transported in a sterile transport medium to the laboratory. The sample must be kept at a controlled temperature during transport and processed promptly in the laboratory to maintain cell viability and avoid contamination.<sup>(4)</sup>

**(c)Percutaneous Umbilical Blood Sampling (PUBS):** PUBS, also known as cordocentesis, is a rare procedure performed between 18 to 24 weeks of gestation. It involves the direct sampling of fetal blood from the umbilical cord to analyze fetal chromosomes and assess specific blood-related conditions.

**Sample Handling and Transport:** The fetal blood sample obtained through PUBS is collected in heparinized syringes to prevent clotting. Special care is taken to ensure the sample's sterility during collection and transportation to the laboratory. The sample should be processed promptly upon arrival to maintain cell viability.<sup>(5)</sup>

**(d)Non-Invasive Prenatal Testing (NIPT):** NIPT is a relatively new and non-invasive screening test that can be performed as early as 9 weeks of gestation. It involves analyzing cell-free fetal DNA (cffDNA) present in the maternal blood to screen for common chromosomal abnormalities and some microdeletion syndromes.

**Sample Handling and Transport:** For NIPT, a maternal blood sample is collected in a standard blood collection tube. The sample is then processed to isolate and analyze the cffDNA. Proper handling and transport of the blood sample are crucial to prevent degradation of the genetic material.<sup>(6)</sup>

### IV. CONVENTIONAL CYTOGENETIC TECHNIQUES

Conventional cytogenetic techniques involve the culturing of fetal cells and the application of various banding methods to visualize and analyze the chromosomes. These methods have been the gold standard for many years in detecting numerical and structural chromosomal abnormalities in prenatal cytogenetics.

**(A) Chromosome Culturing and Banding Methods:**

**(a) Chromosome Culturing:** In conventional cytogenetics, fetal cells obtained through amniocentesis, chorionic villus sampling (CVS), or other invasive procedures are cultured in the laboratory. The cells are stimulated to divide, and this allows for the observation of chromosomes during their active state of replication.<sup>(7)</sup>

**(b) G-Banding (Giemsa Banding):** G-banding is the most widely used banding method in prenatal cytogenetics. After chromosome culturing, the chromosomes are treated with the Giemsa stain, which produces characteristic dark and light bands along the length of each chromosome. G-banding allows for the identification of individual chromosomes and the detection of numerical and structural abnormalities.<sup>(7,8)</sup>

(c) **C-Banding (Constitutive Heterochromatin Banding):** C-banding involves specific staining techniques that highlight regions of constitutive heterochromatin, which are regions of condensed chromatin found near the centromeres and other specific chromosomal locations. C-banding is useful in identifying certain structural chromosomal abnormalities.<sup>(8)</sup>

(d) **R-Banding (Reverse Banding):** R-banding is the reverse version of G-banding, where the dark and light bands are inverted. R-banding can provide additional information in specific chromosomal rearrangements.<sup>(7)</sup>

### **(B) Karyotype Analysis and its Significance:**

Karyotype analysis is the systematic arrangement and classification of chromosomes based on their number, size, shape, and banding patterns. It provides a visual representation of the entire set of chromosomes of an individual, known as the karyotype. Karyotype analysis is essential in identifying numerical and structural chromosomal abnormalities, including:

- **Numerical Abnormalities:** Karyotype analysis can identify conditions like trisomies (e.g., Trisomy 21, Trisomy 18), monosomies, and polyploidies (e.g., triploidy) caused by an abnormal number of chromosomes.
- **Structural Abnormalities:** Karyotype analysis can detect structural rearrangements, such as translocations, inversions, deletions, and duplications, which may result in developmental disorders.

Karyotype analysis remains a valuable tool in the diagnosis of many chromosomal abnormalities and provides a comprehensive view of the fetal chromosome complement.<sup>(9)</sup>

### **(C) Limitations of Conventional Cytogenetics and the Need for Complementary Approaches:**

While conventional cytogenetic techniques have been instrumental in prenatal diagnosis, they have some limitations, including:

- **Limited Resolution:** Conventional cytogenetics may not detect small chromosomal abnormalities, such as microdeletions or microduplications, which can be missed using G-banding alone.
- **Culturing Time:** Chromosome culturing and banding methods require several days to obtain results, which may delay diagnosis and decision-making for expectant parents.
- **Mosaicism Detection:** Conventional cytogenetics might not identify low-level mosaicism, where some cells have abnormal chromosomal content while others appear normal.
- **Fetal Demise Risk:** Invasive procedures like amniocentesis or CVS carry a small risk of fetal loss, which can be a concern for some pregnant individuals.

**To overcome these limitations, complementary approaches have been developed, including:**

- **Molecular Cytogenetic Techniques** like Fluorescence In Situ Hybridization (FISH), Array Comparative Genomic Hybridization (aCGH), and Next-Generation Sequencing (NGS), which offer higher resolution and quicker results for specific abnormalities.
- **Non-Invasive Prenatal Testing (NIPT)** using cell-free fetal DNA from maternal blood, which can screen for common chromosomal aneuploidies without the need for invasive procedures.<sup>(8,9)</sup>

## **V. MOLECULAR CYTOGENETIC TECHNIQUES**

Molecular cytogenetic techniques have significantly enhanced the capabilities of prenatal genetic testing, enabling the detection of chromosomal abnormalities with higher resolution and accuracy. These techniques involve the use of advanced molecular tools to analyze the genetic material at a more detailed level.

### **(a) Fluorescence in situ hybridization (FISH) for targeted chromosomal analysis:**

FISH is a widely used molecular cytogenetic technique that allows for the visualization and identification of specific chromosomal regions. In prenatal cytogenetics, FISH is particularly valuable for targeted analysis of known chromosomal abnormalities. Specific DNA probes labeled with fluorescent dyes are used to hybridize to complementary sequences on the chromosomes of interest. By observing the fluorescence pattern, the presence or absence of the target chromosome or chromosomal region can be determined.

FISH is especially useful in rapidly detecting common aneuploidies, such as Trisomy 21, Trisomy 18, and Trisomy 13, in prenatal samples. It is also employed to investigate microdeletion syndromes, such as DiGeorge syndrome (22q11.2 deletion), Prader-Willi syndrome, and Angelman syndrome, among others.<sup>(10)</sup>

### **(b) Array Comparative Genomic Hybridization (aCGH) and its application in detecting submicroscopic chromosomal imbalances:**

aCGH is a high-resolution molecular cytogenetic technique that enables the detection of submicroscopic chromosomal imbalances, which may not be visible using conventional cytogenetics or FISH. In aCGH, DNA from the patient and a reference sample (typically a healthy individual) are labeled with different fluorochromes and co-hybridized to a microarray containing thousands of DNA probes representing the entire genome. Any differences in DNA copy number between the patient and reference samples can be detected by comparing the fluorescence signals.

In prenatal cytogenetics, aCGH is particularly valuable in identifying small deletions or duplications, called copy number variations (CNVs), associated with developmental disorders and intellectual disabilities. It has significantly increased the diagnostic yield in cases with unexplained developmental delays and multiple congenital anomalies.<sup>(11)</sup>

**(c) Next-Generation Sequencing (NGS) for whole-genome analysis and detection of rare genetic variants:** NGS, also known as high-throughput sequencing, is a revolutionary technology that allows for rapid and comprehensive sequencing of the entire genome or specific gene regions. In prenatal cytogenetic, NGS can be applied to detect both chromosomal abnormalities and rare genetic variants associated with genetic disorders.

Whole-genome sequencing using NGS can identify large chromosomal abnormalities, such as aneuploidies, as well as structural rearrangements, similar to conventional cytogenetics. Additionally, NGS can detect single-nucleotide variants (SNVs) and small insertions or deletions, providing valuable information about genetic conditions caused by specific gene mutations.<sup>(12)</sup>

**(d) Non-Invasive Prenatal Testing (NIPT) using cell-free fetal DNA in maternal blood:**

NIPT is a non-invasive screening test for common fetal chromosomal aneuploidies, such as Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome), among others. The test is performed using a blood sample from the pregnant individual, which contains cell-free fetal DNA (cffDNA) released from the placenta into the maternal bloodstream.

NIPT utilizes advanced sequencing techniques to analyze the relative amounts of fetal and maternal DNA for specific chromosomes of interest. By comparing the ratios, the test can identify an increased or decreased representation of chromosomes, indicative of possible aneuploidies.

NIPT is considered a highly sensitive and specific screening test for common chromosomal abnormalities, and it has the advantage of being non-invasive, posing no risk to the fetus.<sup>(13)</sup>

## VI. PRENATAL CYTOGENETIC APPLICATIONS

Prenatal cytogenetics plays a crucial role in the detection and diagnosis of various chromosomal disorders and genetic conditions in the developing fetus. Here are some important applications of prenatal cytogenetics:

**(a) Detection and Diagnosis of Common Chromosomal Disorders:** Prenatal cytogenetic testing is commonly used to identify and diagnose common chromosomal disorders caused by numerical abnormalities, such as Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome). These conditions result from the presence of an extra copy of chromosome 21, 18, or 13, respectively.

Early detection of these chromosomal disorders through prenatal testing allows expectant parents to make informed decisions about their pregnancy, prepare for the care of a child with special needs, and receive appropriate medical care and support.<sup>(14)</sup>

**(b) Identification of Sex Chromosome Aneuploidies:** Prenatal cytogenetics can also detect sex chromosome aneuploidies, where there is an abnormal number of X and/or Y chromosomes. Common sex chromosome aneuploidies include:

- Turner syndrome (45,X): A female fetus with only one X chromosome and no Y chromosome.
- Klinefelter syndrome (47, XXY): A male fetus with an extra X chromosome (XXY).
- Triple X syndrome (47, XXX): A female fetus with an extra X chromosome (XXX).
- XYY syndrome (47, XYY): A male fetus with an extra Y chromosome (XYY).

Each sex chromosome aneuploidy has its clinical features and potential implications for the individual's health and development.<sup>(15)</sup>

**(c) Evaluation of Structural Chromosomal Rearrangements:** Prenatal cytogenetic can identify structural chromosomal rearrangements, such as translocations, inversions, deletions, and duplications. These rearrangements can be associated with developmental abnormalities and may have implications for the individual's health.

For example, a balanced translocation in one of the parents may not cause any health issues for them but can lead to unbalanced chromosomal content in the fetus, resulting in developmental disorders or pregnancy loss.<sup>(16,17)</sup>

**(d) Screening for Microdeletion and Microduplication Syndromes:** Microdeletion and microduplication syndromes involve small deletions or duplications of specific chromosomal regions. These conditions may not be easily detectable using conventional cytogenetic techniques but can be identified through molecular cytogenetic techniques like array comparative genomic hybridization (aCGH) and next-generation sequencing (NGS).

Examples of microdeletion syndromes include DiGeorge syndrome (22q11.2 deletion) and Prader-Willi syndrome, while microduplication syndromes include 1q21.1 duplication syndrome. Prenatal screening for these syndromes can aid in early diagnosis and management.<sup>(16,17)</sup>

## VII. CLINICAL IMPLICATIONS AND GENETIC COUNSELING

### (a) Genetic Counseling Sessions:

When prenatal cytogenetic results are available, genetic counselors play a critical role in interpreting the results and communicating the findings to the expectant parents. Genetic counseling sessions are conducted to provide a clear understanding of the test results, including the presence or absence of chromosomal abnormalities and the implications for the fetus.<sup>(18)</sup>

### (b) Explanation of Chromosomal Abnormalities:

Genetic counselors explain the specific chromosomal abnormality detected, its potential impact on the fetus's development and health, and the range of clinical features associated with the condition.<sup>(19)</sup>

### (c) Discussion of Prognosis and Management:

Genetic counselors discuss the likely outcomes and long-term prognosis of the identified chromosomal abnormality. They also provide information about available medical interventions, supportive care, and available resources.

### (d) Informed Decision-Making:

Genetic counselors support expectant parents in making informed decisions based on the test results. These decisions may involve continuation of the pregnancy, considering therapeutic options, or planning for the birth and care of a child with special needs.<sup>(20,21)</sup>

### Counseling Strategies for Couples Facing Abnormal Prenatal Cytogenetic Results:

- ✓ Empathetic and Supportive Approach: Genetic counselors adopt an empathetic and supportive approach while delivering difficult news to expectant parents. They acknowledge the emotional impact of the results and provide a safe space for parents to express their feelings and concerns.
- ✓ Tailored Communication: Counseling sessions are tailored to the individual needs and understanding of the parents. Complex medical terminology is explained in understandable language to facilitate comprehension.
- ✓ Presenting Options: Genetic counselors present all available options to the parents and provide unbiased information about the risks, benefits, and limitations of each choice. This may include discussing the possibility of additional testing, considering medical interventions, or preparing for the care of a child with special needs.
- ✓ Providing Emotional Support: Genetic counselors offer emotional support throughout the decision-making process. They address any guilt, anxiety, or grief experienced by the parents and encourage open dialogue.<sup>(20,21)</sup>

### Impact of Prenatal Genetic Testing on Pregnancy Management and Decision-Making:

- ✓ Early Detection and Planning: Prenatal genetic testing allows for the early detection of chromosomal abnormalities, which enables parents to make informed decisions about their pregnancy and prepare for the birth of a child with special needs. Early detection also allows for better management and planning of the baby's medical care and support after birth.
- ✓ Pregnancy Continuation or Termination: Prenatal genetic testing results may influence the decision to continue or terminate the pregnancy, depending on the severity of the chromosomal abnormality and the parents' values and beliefs.
- ✓ Preparation and Support Services: Parents who receive abnormal prenatal cytogenetic results can benefit from accessing support services, such as specialized medical care, educational resources, and support groups for families with similar conditions.
- ✓ Ethical Considerations: Prenatal genetic testing raises complex ethical considerations related to reproductive choices, parental autonomy, and the well-being of the unborn child. Genetic counseling provides a forum to explore these ethical issues and assists parents in making decisions in line with their values and beliefs.<sup>(20,21)</sup>

## VIII. ADVANCEMENTS AND FUTURE DIRECTIONS

### 1. Emerging Technologies and their Potential Role:

#### (a) Single-Cell Sequencing:

Single-cell sequencing technologies have the potential to analyze the genetic content of individual cells, allowing for the detection of chromosomal abnormalities at a higher resolution, especially in cases of mosaicism or small subpopulations of abnormal cells.<sup>(22,23)</sup>

#### (b) Long-Read Sequencing:

Long-read sequencing techniques enable the analysis of longer DNA fragments, which can aid in detecting complex structural chromosomal rearrangements and repetitive regions of the genome, not easily resolved by short-read sequencing methods.<sup>(22)</sup>

#### (c) Genome Editing:

Advancements in genome editing technologies, such as CRISPR-Cas9, offer potential applications in correcting specific genetic mutations responsible for certain chromosomal disorders, opening possibilities for therapeutic interventions.<sup>(23)</sup>

#### (d) Non-Invasive Prenatal Testing (NIPT) Expansion:

NIPT is likely to expand its scope beyond common aneuploidies to screen for additional genetic conditions and microdeletion syndromes with improved accuracy.<sup>(22)</sup>

## **2. Integration of Prenatal Genetic Testing with Other Diagnostic Modalities:**

### **(a) Imaging Techniques:**

Integrating prenatal genetic testing with advanced imaging modalities, such as high-resolution ultrasound, magnetic resonance imaging (MRI), and fetal echocardiography, can provide a comprehensive evaluation of fetal health and assist in the management of complex cases.<sup>(24)</sup>

### **(b) Preimplantation Genetic Testing (PGT):**

For couples undergoing in vitro fertilization (IVF), PGT allows for the genetic analysis of embryos before implantation, enabling the selection of unaffected embryos for transfer, reducing the risk of certain genetic disorders in the offspring.<sup>(23)</sup>

### **(c) Postnatal Genetic Testing:**

In cases where prenatal genetic testing results are inconclusive or unavailable, postnatal genetic testing may be warranted to confirm the diagnosis and guide medical management.<sup>(24)</sup>

## **3. Ethical, Legal, and Social Implications of Prenatal Genetic Testing:**

### **(a) Ethical Considerations:**

As prenatal genetic testing becomes more comprehensive and accessible, ethical questions regarding the scope of testing, the management of incidental findings, and the use of genetic information may arise, requiring ongoing discussions and guidelines.<sup>(22)</sup>

### **(b) Informed Consent and Counseling:**

Ensuring that expectant parents receive accurate information, comprehensive genetic counseling, and informed consent is critical, considering the complex nature of genetic testing and its potential impact on family dynamics.<sup>(24,25)</sup>

**(c) Genetic Discrimination:** Prenatal genetic testing results may have implications for insurance coverage, employment opportunities, and social stigmatization. Legislation and policies need to protect individuals and families from genetic discrimination.

### **(d) Societal Attitudes:**

Societal attitudes toward disability and genetic conditions can influence the decisions of expectant parents regarding prenatal testing and pregnancy management. Ensuring inclusivity and support for individuals with genetic conditions is crucial.<sup>(25)</sup>

## **IX. CONCLUSION**

Prenatal cytogenetic analysis remains a cornerstone of prenatal diagnosis, aiding in the early identification of genetic abnormalities in the developing fetus. Technological advancements continue to enhance the accuracy and scope of prenatal genetic testing, further contributing to the well-being of expectant parents and their unborn children. However, the ethical challenges and counseling complexities require ongoing consideration to ensure the responsible and informed use of prenatal cytogenetic techniques.

## REFERENCE:

1. Reardon S. A historical and ethical perspective on modern prenatal genetic testing. *Semin Fetal Neonatal Med.* 2018; 23(1): 13-19. DOI: 10.1016/j.siny.2017.09.001.
2. Mikael Häggström, MD, Jacquelyn V Halliday, MSGeralyn M Messerlian, PhDGlenn E Palomaki, PhD. "Patient education: Should I have a screening test for Down syndrome during pregnancy? (Beyond the Basics)". Feb 16, 2023.
3. Pös, Ondrej; Budiš, Jaroslav; Szemes, Tomáš (2019). "Recent trends in prenatal genetic screening and testing". *F1000Research.* 8: 764. doi:10.12688/f1000research.16837.1. ISSN 2046-1402. PMC 6545823. PMID 31214330.
4. Dugoff L, Norton ME, Kuller JA, editor. *The Prenatal Diagnosis and Treatment of Genetic Disorder.* John Wiley & Sons; 2016. (Chapter 6: Invasive Prenatal Diagnosis Technique).
5. Dey M, Sharma S, Aggarwal S. Prenatal screening methods for aneuploidies. *N Am J Med Sci.* 2013;5(3):182-190. doi:10.4103/1947-2714.109180
6. Deans ZC, Allen S, Jenkins L, et al. Recommended practice for laboratory reporting of non-invasive prenatal testing of trisomies 13, 18 and 21: a consensus opinion. *Prenat Diagn.* 2017;37(7):699-704. doi:10.1002/pd.5068.
7. Nowell PC, Hungerford DA. "A minute chromosome in human chronic granulocytic leukemia". pp. 1497–1501 in "National Academy of Sciences". *Science.* 132 (3438): 1488–1501. 18 November 1960. doi:10.1126/science.132.3438.1488. PMID 17739576.
8. Gupta, P. K. (2007). *Cytogenetics.* Rastogi Publications. ISBN 978-81-7133-737-8.
9. Gardner RJM, Sutherland GR, Shaffer LG. *Chromosome Abnormalities and Genetic Counseling.* 4<sup>th</sup> edition. Oxford University Press; 2011. (Chapter 7: Cytogenetics).
10. Nicolaides KH. Noninvasive prenatal testing of fetal aneuploidies by maternal plasma DNA sequencing: Clinical utility and limitations. *Ultrasound in Obstetrics & Gynecology.* 2013; 41(3): 301-314. DOI: 10.1002/uog.12377.
11. Vorsanova SG, Yurov YB, Iourov IY. Human interphase chromosomes: a review of available molecular cytogenetic technologies. *Molecular cytogenetics.* 2010 Dec;3(1):1-5.
12. Liehr T, Claussen U. Current developments in human molecular cytogenetic techniques. *Current Molecular Medicine.* 2002 May 1;2(3):283-97.
13. Bridge JA. Cytogenetic and molecular cytogenetic techniques in orthopaedic surgery. *JBJS.* 1993 Apr 1;75(4):606-14.
14. Savage MS, Mourad MJ, Wapner RJ. Evolving applications of microarray analysis in prenatal diagnosis. *Current opinion in obstetrics & gynecology.* 2011 Apr;23(2):103.
15. Nicolaides KH, Syngelaki A, Ashoorn G, Birdir C, Touzet G. Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. *Am J Obstet Gynecol.* 2012;207(5):374.e6. DOI:10.1016/j.ajog.2012.02.1.
16. Bui TH. Prenatal cytogenetic diagnosis: gone FISHing, BAC soon!. *Ultrasound in Obstetrics and Gynecology: The Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology.* 2007 Sep;30(3):247-51.
17. Mark HF, Jenkins R, Miller WA. Current applications of molecular cytogenetic technologies. *Annals of Clinical & Laboratory Science.* 1997 Jan 1;27(1):47-56.
18. Roche MI, Berg JS. Incidental findings with genomic testing: implications for genetic counseling practice. *Current genetic medicine reports.* 2015 Dec;3(4):166-76.
19. American College of Obstetricians and Gynecologists' Committee on Genetics. Committee Opinion No. 581: The Use of Chromosomal Microarray Analysis in Prenatal Diagnosis. *Obstet Gynecol.* 2013; 122(6): 1374-1377. DOI: 10.1097/01.AOG.0000438965.74924.cc.
20. Murphy R, Ellard S, Hattersley AT. Clinical implications of a molecular genetic classification of monogenic  $\beta$ -cell diabetes. *Nature clinical practice Endocrinology & metabolism.* 2008 Apr;4(4):200-13.
21. Grimes DA, Snively GR. Patients' understanding of medical risks: implications for genetic counseling. *Obstetrics & Gynecology.* 1999 Jun 1;93(6):910-4.
22. Srinivasan BS, Evans EA, Flannick J, Patterson AS, Krishnan AR, Socolovsky, et al. Towards precision medicine in the clinic: from biomarker discovery to novel therapeutics. *Trends Pharmacol Sci.* 2015;36(11):602-613. DOI:10.106/j.tips.2015.07.006.
23. Medsinge A, Nischal KK. Pediatric cataract: challenges and future directions. *Clinical Ophthalmology.* 2015 Jan 7:77-90.
24. Sorrell AD, Espenschied CR, Culver JO, Weitzel JN. Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome: current status of clinical applications and future directions. *Molecular diagnosis & therapy.* 2013 Feb;17:31-47.
25. El-Hattab AW, Almannai M, Sutton VR. Newborn screening: history, current status, and future directions. *Pediatric Clinics.* 2018 Apr 1;65(2):389-405.